Preclinical studies have shown that potential inhibitors of the NF-κB pathway lead to desirable outcomes in rodent models of ischemic stroke, such as reduced infarct size and inflammatory biomarkers [138,139,140]. This evidence concerns the gene NFKB1 and ischemic stroke.